Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Rep. Gilbert Ray Cisneros, Jr. disclosed buying between $50,001 and $100,000 of Eli Lilly shares on June 10, reported in a filing on July 2.
• Eli Lilly posted better-than-expected quarterly results, with EPS of $8.55 versus $6.97 expected and revenue of $19.8 billion versus $17.82 billion expected, while raising full-year FY2026 guidance to 35.5–37.0 EPS.
• The company also announced a quarterly dividend of $1.73 per share, payable September 10, and the stock has drawn broadly positive sentiment from analysts and recent headlines tied to GLP-1 demand and growth prospects.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $50,001 and $100,000 in Eli Lilly and Company stock on June 10th. The trade occurred in the Representative's "150 MAIN STREET TRUST > WELLS FARGO ADVISORS" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of The Descartes Systems Group NASDAQ: DSGX on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Texas Roadhouse NASDAQ: TXRH on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Texas Capital Bancshares NASDAQ: TCBI on 6/30/2026.
• Sold $1,001 - $15,000 in shares of SoftBank Group OTCMKTS: SFTBF on 6/30/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 6/30/2026.
• Sold $1,001 - $15,000 in shares of RBC Bearings NYSE: RBC on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Microchip Technology NASDAQ: MCHP on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of HealthEquity NASDAQ: HQY on 6/30/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 6/30/2026.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 6/30/2026.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,208.37 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,238.00. The business has a 50-day simple moving average of $1,065.45 and a 200 day simple moving average of $1,028.14. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.14 trillion, a price-to-earnings ratio of 42.93, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the company earned $3.34 EPS. The company's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Coverage highlighted Eli Lilly as a leader in GLP-1 therapies with an expanding pipeline and diversified growth strategy, reinforcing the bull case despite the stock’s premium valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Shares were lifted by optimism around GLP-1 Medicare inclusion and strong reported results, which investors view as supportive of continued demand and revenue growth. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Another bullish note argued that artificial intelligence could become a long-term growth tailwind for Eli Lilly by improving drug development and operational efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Repeated mentions in pharmaceutical and medical stock roundups suggest Lilly remains one of the sector’s preferred large-cap names for investors seeking growth exposure. Pharmaceutical Stocks To Follow Now - July 2nd
• Positive Sentiment: Additional commentary pointed to Lilly’s appeal to long-term, high-conviction investors, including billionaire hedge fund manager Cliff Asness, adding to the stock’s credibility as a favored healthcare holding. Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
• Neutral Sentiment: One item noted a leadership change at Lilly Korea, which appears operationally routine and unlikely to move the stock on its own. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: General industry pieces about pharmaceutical growth and the sector’s $2 trillion sales trajectory are supportive of sentiment, but they do not add a specific new catalyst for Lilly. Can pharma sustain its $2T trajectory?

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $12,976,634,000. Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP grew its holdings in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. grew its holdings in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock valued at $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. UBS Group reissued a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research report on Monday, June 22nd. HSBC cut shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and cut their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Wolfe Research reissued an "outperform" rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Rothschild & Co Redburn raised their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $1,235.07.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.